{"id":"W4410805300","doi":"10.1200/jco.2025.43.16_suppl.tps9600","title":"A phase 1, open-label, dose expansion cohort of the tolerability of tolododekin alfa (ANK-101) in combination with cemiplimab in cutaneous squamous cell carcinoma.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Nonmelanoma Skin Cancer Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Tolerability; Open label; Cohort; Oncology; Internal medicine; Adverse effect","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00218089,0.001985281,0.001845146,0.0005458252,0.0006813153,0.001113821,0.0009572683,0.001342772,0.005926213],"category_scores_gemma":[0.001254078,0.0006569871,0.001657007,0.000359106,0.001002861,0.001311055,0.0004608639,0.004029357,0.001779085],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001383969,"about_ca_system_score_gemma":0.001846843,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001078455,"about_ca_topic_score_gemma":0.002282055,"domain_scores_codex":[0.9994098,0.000220122,0.00002404345,0.0001186043,0.00008189469,0.0001455849],"domain_scores_gemma":[0.9986166,0.0001901141,0.0002965698,0.0001599923,0.0001310344,0.0006056808],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.5634775,0.2363358,0.01584388,0.0007635142,0.001397592,0.0005272852,0.0006234216,0.003406991,0.06523348,0.0002281883,0.008554061,0.1036083],"study_design_scores_gemma":[0.1725616,0.7966556,0.02042939,0.00002472114,0.0003659862,0.0003923438,0.0001157304,0.001093845,0.005247644,0.0001747039,0.002904444,0.00003406332],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9923879,0.000516504,0.0003963203,0.0001904544,0.00006643389,0.003509252,0.001630047,0.0000779148,0.001225189],"genre_scores_gemma":[0.9832987,0.0007162541,0.001713,0.0007245712,0.0001884108,0.005284206,0.004157917,0.00005685769,0.003860091],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005926213,"threshold_uncertainty_score":0.01982516,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07668714375346083,"score_gpt":0.4439034854278719,"score_spread":0.3672163416744111,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}